Role of reactive oxygen species in hyperadrenergic hypertension: Biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin A (Chga) gene

Circulation: Cardiovascular Genetics

Volumn 3, Issue 5, 2010, Pages 414-425

  Gayen, Jiaur R ^a   Zhang, Kuixing ^a   RamachandraRao, Satish P ^a   Mahata, Manjula ^a   Chen, Yuqing ^a   Kim, Hyung Suk ^c   Naviaux, Robert K ^a   Sharma, Kumar ^a,b   Mahata, Sushil K ^a,b   O'Connor, Daniel T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chromogranin A; Hypertension; Nitric oxide; Reactive oxygen species

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; APOCYNIN; BETA 2 ADRENERGIC RECEPTOR; CHROMOGRANIN A; CLONIDINE; CREATININE; HYDROGEN PEROXIDE; ISOPROSTANE; MESSENGER RNA; NITRIC OXIDE; NORADRENALIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; GENE LOCUS; GENE TARGETING; GENETIC VARIABILITY; HYPERTENSION; KNOCKOUT MOUSE; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; WILD TYPE;

ACETOPHENONES; ADRENOCORTICAL HYPERFUNCTION; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATECHOLAMINES; CELL LINE; CHROMOGRANIN A; CLONIDINE; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; ENZYME INHIBITORS; HUMANS; HYDROGEN PEROXIDE; HYPERTENSION; ISOPROSTANES; KIDNEY; MICE; MICE, KNOCKOUT; NITRIC OXIDE; OXIDATIVE STRESS; PODOCYTES; REACTIVE OXYGEN SPECIES;

MUS;

EID: 78649364973     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.109.924050     Document Type: Article

References (68)

1. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension. 1983;5:86-99.
2. Westfall TC, Meldrum MJ. Alterations in the release of norepinephrine at the vascular neuroeffector junction in hypertension. Annu Rev Pharmacol Toxicol. 1985;25:621-641.
3. Borkowski KR, Quinn P. Adrenaline and the development of spontaneous hypertension in rats. J Auton Pharmacol. 1985;5:89-100.
4. Ohlstein EH, Kruse LI, Ezekiel M, Sherman SS, Erickson R, DeWolf WE Jr, Berkowitz BA. Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther. 1987;241:554-559.
5. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 1992;49:497-528.
6. Taupenot L, Harper KL, O'Connor DT. Mechanisms of disease: the chromogranin-secretogranin family. N Engl J Med. 2003;348: 1134-1149.
7. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK, Anouar Y. Chromogranins A and B and secretogranin 11: evolutionary and functional aspects. Acta Physiol (Oxf). 2008;192:309-324.
8. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HP, O'Connor DT. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab. 1990;71:360-369.
9. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release: a discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist J Clin Invest. 1997;100:1623-1633.
10. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, O'Connor DT. Chromogranin A in human hypertension: influence of heredity. Hypertension. 1995;26:213-220.
11. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002; 20:1335-1345.
12. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 2007;115:2271-2281.
13. Chen Y, Rao F, Rodriguez-Flores JL, Mahata M, Fung MM, Stridsberg M, Vaingankar SM, Wen G, Salem RM, Das M, Cockburn MG, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, Taupenot L, O'Connor DT. Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol. 2008;52:1468-1481.
14. Chen Y, Rao F, Rodriguez-Flores JL, Mahapatra NR, Mahata M, Wen G, Salem RM, Shih PA, Das M, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, O'Connor DT. Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int. 2008;74:115-125.
15. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest. 2005;115: 1942-1952.
16. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998;16:291-303.
17. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension. 2000;36: 878-884.
18. Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. J Clin Invest. 2001;107:23-25.
19. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep. 2002;4:160-166.
20. Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension. 2002;39: 809-814.
21. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541-546.
22. Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res. 2001; 24:116-123.
23. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001;37:554-560.
24. Romero JC, Reckelhoff JF. State-of-the-art lecture: role of angiotensin and oxidative stress in essential hypertension Hypertension. 1999;34:943-949.
25. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension. 1998;31:189-193.
26. Ward NC, Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol. 2006;33:872-876.
27. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: the role of superoxide anion. Hypertension. 1999;34:539-545.
28. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res. 1997;236:248-258.
29. Naviaux RK, Le TP, Bedelbaeva K, Leferovich J, Gourevitch D, Sachadyn P, Zhang XM, Clark L, Heber-Katz E. Retained features of embryonic metabolism in the adult mrl mouse. Mol Genet Metab. 2009; 96:133-144.
30. Cuzzocrea S, Mazzon E, Dugo L, Di Paola R, Caputi AP, Salvemini D. Superoxide: a key player in hypertension. FASEB J. 2004;18:94-101.
31. Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, Ziyadeh FN, Badr KF. F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int. 2000;58:1963-1972.
32. Alexander SP, Mathie A, Peters JA. Guide to receptors and channels (grac). 3rd edition. Br J Pharmacol. 2008;153(Suppl 2):S1-S209.
33. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
34. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005;25:279-286.
35. Krier JD, Rodriguez-Porcel M, Best PJ, Romero JC, Lerman A, Lerman LO. Vascular responses in vivo to 8-epi pgf(2alpha) in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol. 2002;283:R303-R308.
36. O'Connor DT, Takiyyuddin MA, Printz MP, Dinh TQ, Barbosa JA, Rozansky DJ, Mahata SK, Wu H, Kennedy BP, Ziegler MG, Wright FA, Schlager G, Parmer RJ. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press. 1999;8:285-295.
37. Kelly RB. Pathways of protein secretion in eukaryotes. Science. 1985; 230:25-32.
38. Kim T, Tao-Cheng J, Eiden LE, Loh YP. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell. 2001; 106:499-509.
39. Courel M, Rodemer C, Nguyen ST, Pance A, Jackson AP, O'Connor DT, Taupenot L. Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. J Biol Chem. 2006;281:38038-38051.
40. Nauseef WM. Biological roles for the Nox family NADPH oxidases. J Biol Chem. 2008;283:16961-16965.
41. Bedard K, Krause KH. The Nox family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87: 245-313.
42. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Sympathoexcitation by central Ang II: roles for At1 receptor upregulation and Nad(p)h oxidase in RVLM. Am J Physiol Heart Circ Physiol. 2005; 288:H2271-H2279.
43. Peterson J.R., Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep. 2006;8: 232-241.
44. Infanger DW, Sharma RV, Davisson RL. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal. 2006;8: 1583-1596.
45. Yamaguchi O, Kaneshiro T, Saitoh S, Ishibashi T, Maruyama Y, Takeishi Y. Regulation of coronary vascular tone via redox modulation in the alpha1-adrenergic-angiotensin-endothelin axis of the myocardium. Am J Physiol Heart Circ Physiol. 2009;296:H226-H232.
46. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. Role of reactive oxygen species and Nad(p)h oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol. 2002;282:C926-C934.
47. Simao S, Fraga S, Jose PA, Soares-da-Silva P. Oxidative stress plays a permissive role in alpha2-adrenoceptor-mediated events in immortalized SHR proximal tubular epithelial cells. Mol Cell Biochem. 2008;315: 31-39.
48. Jackson EK, Gillespie DG, Zhu C, Ren J, Zacharia LC, Mi Z. Alpha2-adrenoceptors enhance angiotensin II-induced renal vasoconstriction: role for NADPH oxidase and RhoA. Hypertension. 2008;51:719-726.
49. Diaz-Cruz A, Guinzberg R, Guerra R, Vilchis M, Carrasco D, Garcia-Vazquez FJ, Pina E. Adrenaline stimulates H2O2 generation in liver via NADPH oxidase. Free Radic Res. 2007;41:663-672.
50. Zeng C, Villar VA, Yu P, Zhou L, Jose PA. Reactive oxygen species and dopamine receptor function in essential hypertension. Clin Exp Hypertens. 2009;31:156-178.
51. Shankland SJ, Pippin JW, Reiser J, Mundel P. Podocytes in culture: past, present, and future. Kidney Int. 2007;72:26-36.
52. Huber TB, Gloy J, Henger A, Schollmeyer P, Greger R, Mundel P, Pavenstadt H. Catecholamines modulate podocyte function. JAmSoc Nephrol. 1998;9:335-345.
53. Endlich N, Endlich K. Camp pathway in podocytes. Microsc Res Tech. 2002;57:228-231.
54. Nishino T. The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury. J Biochem. 1994;116:1-6.
55. Nishino T, Okamoto K, Kawaguchi Y, Hori H, Matsumura T, Eger BT, Pai EF. Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase: identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutant. J Biol Chem. 2005;280:24888-24894.
56. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
57. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, Krause KH. Nox4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007;406:105-114.
58. Tyler BJ. Reaction of hydrogen peroxide and nitric oxide. Nature. 1962; 195:279-280.
59. Noronha-Dutra AA, Epperlein MM, Woolf N. Reaction of nitric oxide with hydrogen peroxide to produce potentially cytotoxic singlet oxygen as a model for nitric oxide-mediated killing. FEBS Lett. 1993;321:59-62.
60. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
61. Queen LR, Ji Y, Xu B, Young L, Yao K, Wyatt AW, Rowlands DJ, Siow RC, Mann GE, Ferro A. Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells. J Physiol. 2006;576:585-594.
62. Sethi R, Adameova A, Dhalla KS, Khan M, Elimban V, Dhalla NS. Modification of epinephrine-induced arrhythmias by N-acetyl-L-cysteine and vitamin E. J Cardiovasc Pharmacol Ther. 2009;14:134-142.
63. Jewett SL, Eddy LJ, Hochstein P. 1s the autoxidation of catecholamines involved in ischemia-reperfusion injury? Free Radic Biol Med. 1989;6: 185-188.
64. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309.
65. Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, Colucci WS. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res. 2003;92:136-138.
66. Amin JK, Xiao L, Pimental DR, Pagano PJ, Singh K, Sawyer DB, Colucci WS. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol. 2001;33:131-139.
67. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension. 2008;51:211-217.
68. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.